These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 15517432)

  • 1. Post-translational modifications of tau protein in Alzheimer's disease.
    Gong CX; Liu F; Grundke-Iqbal I; Iqbal K
    J Neural Transm (Vienna); 2005 Jun; 112(6):813-38. PubMed ID: 15517432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-translational modifications of tau protein: implications for Alzheimer's disease.
    Martin L; Latypova X; Terro F
    Neurochem Int; 2011 Mar; 58(4):458-71. PubMed ID: 21215781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-translational modifications of tau protein.
    Pevalova M; Filipcik P; Novak M; Avila J; Iqbal K
    Bratisl Lek Listy; 2006; 107(9-10):346-53. PubMed ID: 17262986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau Abnormalities and the Potential Therapy in Alzheimer's Disease.
    Almansoub HAMM; Tang H; Wu Y; Wang DQ; Mahaman YAR; Wei N; Almansob YAM; He W; Liu D
    J Alzheimers Dis; 2019; 67(1):13-33. PubMed ID: 30507581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
    Liu F; Zaidi T; Iqbal K; Grundke-Iqbal I; Merkle RK; Gong CX
    FEBS Lett; 2002 Feb; 512(1-3):101-6. PubMed ID: 11852060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease.
    Marcus JN; Schachter J
    J Neurogenet; 2011 Dec; 25(4):127-33. PubMed ID: 22091726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degradation or aggregation: the ramifications of post-translational modifications on tau.
    Park S; Lee JH; Jeon JH; Lee MJ
    BMB Rep; 2018 Jun; 51(6):265-273. PubMed ID: 29661268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies.
    Alonso AC; Li B; Grundke-Iqbal I; Iqbal K
    Curr Alzheimer Res; 2008 Aug; 5(4):375-84. PubMed ID: 18690834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration.
    Wang JZ; Xia YY; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2013; 33 Suppl 1():S123-39. PubMed ID: 22710920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology.
    Kalyaanamoorthy S; Opare SK; Xu X; Ganesan A; Rao PPN
    Curr Alzheimer Res; 2024; 21(1):24-49. PubMed ID: 38623984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease.
    Kovacech B; Novak M
    Curr Alzheimer Res; 2010 Dec; 7(8):708-16. PubMed ID: 20678071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
    Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
    Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-translational modifications in Alzheimer's disease and the potential for new biomarkers.
    Russell CL; Koncarevic S; Ward MA
    J Alzheimers Dis; 2014; 41(2):345-64. PubMed ID: 24662105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
    Chen F; David D; Ferrari A; Götz J
    Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Nat Med; 1996 Aug; 2(8):871-5. PubMed ID: 8705855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain.
    Ercan-Herbst E; Ehrig J; Schöndorf DC; Behrendt A; Klaus B; Gomez Ramos B; Prat Oriol N; Weber C; Ehrnhoefer DE
    Acta Neuropathol Commun; 2019 Dec; 7(1):192. PubMed ID: 31796124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules.
    González C; Farías G; Maccioni RB
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1117-27. PubMed ID: 9846894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies.
    Šimić G; Babić Leko M; Wray S; Harrington C; Delalle I; Jovanov-Milošević N; Bažadona D; Buée L; de Silva R; Di Giovanni G; Wischik C; Hof PR
    Biomolecules; 2016 Jan; 6(1):6. PubMed ID: 26751493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies.
    Xia Y; Prokop S; Giasson BI
    Mol Neurodegener; 2021 Jun; 16(1):37. PubMed ID: 34090488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.